Modulation of MHC-E transport by viral decoy ligands is required for RhCMV/SIV vaccine efficacy.


T cell responses exclusively targeting MHC-II-restricted epitopes. These responses were comparable in magnitude and differentiation to responses elicited by 68-1 vectors, but did not protect against SIV. Thus, Rh67-enabled direct priming of MHC-E-restricted T cells is crucial for RhCMV/SIV vaccine efficacy.

MIDAS Network Members